The U.S. Food and Drug Administration (FDA) has approved the first generic version of liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used to lower blood glucose (sugar) in people with type 2 diabetes. This generic version references an FDA-approved version of liraglutide called Victoza, meaning it has been shown to have the same active ingredient, safety, and effectiveness as the FDA-approved brand-name drug. Generic liraglutide is indicated for adults and children aged 10 and older who have type 2 diabetes, as an addition to diet and exercise. It’s administered as a once-daily injection.

According to the FDA, the approval comes amid a shortage of GLP-1 drugs, including liraglutide, driven by surging demand. By greenlighting the drug, the FDA aims to improve access and affordability, potentially easing the financial burden for people managing diabetes.

“Generic drugs provide additional treatment options which are generally more affordable for patients,” said Dr. Iilun Murphy, director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective, and high-quality generic drug products.”

GLP-1 medications like liraglutide help manage type 2 diabetes by mimicking a natural hormone that improves how the body releases insulin after meals. They also slow down digestion and reduce appetite, which can help control blood sugar levels more effectively.

Meeting Unmet Demand

GLP-1 medications like liraglutide, exenatide (Byetta), dulaglutide (Trulicity), tirzepatide (Mounjaro and Zepbound), and semaglutide (Ozempic, Wegovy, and Rybelsus) have emerged in recent years as promising treatments for helping to manage blood sugar levels and reduce long-term complications of type 2 diabetes. However, their high costs have posed a barrier for many, while shortages have made them harder to obtain. The introduction of a lower-cost generic could address both challenges, offering an option to those unable to afford brand-name alternatives or having trouble accessing the drugs.

Notably, as with any other treatment, liraglutide can cause side effects. These include nausea, diarrhea, vomiting, and decreased appetite. It also carries warnings for more serious risks such as thyroid tumors, pancreatitis, and kidney problems.

If you are living with type 2 diabetes and are curious about GLP-1 medications or other treatment options, talk to your healthcare provider to learn about the potential benefits and risks. They can help you find the best approach for managing your condition.

Learn more about the latest diabetes treatment and research.

Find Your Team

On DiabetesTeam, the social network for people living with type 2 diabetes and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with diabetes.

Have you experienced challenges accessing GLP-1 medications? How have you navigated shortages or high costs? Share your tips and experiences in a comment below, start a conversation on your Activities page, or connect with like-minded members in Groups.